Exploration of pathomechanism using comprehensive analysis of serum cytokines in polymyositis/dermatomyositis-interstitial lung disease

被引:41
|
作者
Matsuda, Shogo [1 ]
Kotani, Takuya [1 ]
Ishida, Takaaki [1 ]
Fukui, Keisuke [2 ]
Fujiki, Youhei [1 ]
Suzuka, Takayasu [1 ]
Nagai, Koji [1 ]
Hata, Kenichiro [1 ]
Shoda, Takeshi [3 ]
Isoda, Kentaro [3 ]
Ito, Yuri [2 ]
Makino, Shigeki [1 ]
Takeuchi, Tohru [1 ]
Arawaka, Shigeki [1 ]
机构
[1] Osaka Med Coll, Dept Internal Med 4, Daigaku Machi 2-7, Takatsuki, Osaka 5698686, Japan
[2] Osaka Med Coll, Res & Dev Ctr, Dept Med Stat, Takatsuki, Osaka, Japan
[3] Yodogawa Christians Hosp, Dept Rheumatol, Osaka, Japan
关键词
polymyositis; dermatomyositis; interstitial lung disease; cytokines; CLINICALLY AMYOPATHIC DERMATOMYOSITIS; POLYMYOSITIS; MYOSITIS; PROGNOSIS; ANTIBODY; FERRITIN; PROGRESS; MDA5;
D O I
10.1093/rheumatology/kez301
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To elucidate the serum cytokine profile and address the pathomechanism of interstitial lung disease (ILD) complicated with PM/DM. Methods Forty patients with PM/DM-ILD were enrolled, and principal components analysis and cluster analysis were performed to classify patients into subgroups. Additionally, we compared cytokine profiles between the survivors and dead patients and between anti-melanoma differentiation-associated gene 5 antibody- and anti-aminoacyl tRNA synthetase antibody-positive ILD patients. We also examined the association of various cytokines with disease activity indicators and prognosis of ILD. Results The principal components analysis data allowed classification of the cytokine profile into three groups: group 1, neutrophilic and M1-macrophage-driven cytokines; group 2, type 1 Th cell-driven and M2-macrophage-induced cytokines; and group 3, M2-macrophage-driven cytokines. Cluster analysis showed the presence of PM/DM-ILD patient groups with high or low levels of total cytokines. Ninety percent of patients who died of ILD were included in clusters with high cytokine levels. Serum cytokine levels of all groups were significantly higher in the anti-melanoma differentiation-associated gene 5 antibody-positive patients than in the anti-aminoacyl tRNA synthetase antibody-positive patients. Groups 1 and 2 significantly correlated with known factors for poor prognosis, such as serum ferritin levels and alveolar-arterial oxygen difference. Serum cytokine levels of patients in group 1 were significantly higher initially and at 2 and 4 weeks in those who died. Conclusion These findings suggested that the activation of monocytes, macrophages and type 1 Th cells, and neutrophils play roles in the pathomechanism of PM/DM-ILD, and group 1 cytokines could be useful biomarkers for predicting prognosis of PM/DM-ILD.
引用
收藏
页码:310 / 318
页数:9
相关论文
共 50 条
  • [1] Interstitial Lung Disease in Polymyositis and Dermatomyositis
    Long, Kathryn
    Danoff, Sonye K.
    CLINICS IN CHEST MEDICINE, 2019, 40 (03) : 561 - +
  • [2] Interstitial lung disease in polymyositis and dermatomyositis
    Marie, I
    Hachulla, E
    Chérin, P
    Dominique, S
    Hatron, PY
    Hellot, MF
    Devulder, B
    Herson, S
    Levesque, H
    Courtois, H
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (06): : 614 - 622
  • [3] Interstitial lung disease in polymyositis and dermatomyositis
    Chen, I-Jung
    Wu, Yeong-Jian Jan
    Lin, Cho-Wei
    Fan, Kang-Wei
    Luo, Shue-Fen
    Ho, Huei-Huang
    Liou, Lieh-Bang
    Tsai, Wen-Pin
    Chen, Ji-Yih
    Yang, Chung-Han
    Kuo, Chang-Fu
    Yu, Kuang-Hui
    CLINICAL RHEUMATOLOGY, 2009, 28 (06) : 639 - 646
  • [4] Serum matrix metalloproteinase levels in polymyositis/dermatomyositis patients with interstitial lung disease
    Nakatsuka, Yoshinari
    Handa, Tomohiro
    Nakashima, Ran
    Tanizawa, Kiminobu
    Kubo, Takeshi
    Murase, Yuko
    Sokai, Akihiko
    Ikezoe, Kohei
    Hosono, Yuji
    Watanabe, Kizuku
    Tokuda, Shinsaku
    Uno, Kazuko
    Yoshizawa, Akihiko
    Tsuruyama, Tatsuaki
    Uozumi, Ryuji
    Nagai, Sonoko
    Hatta, Kazuhiro
    Taguchi, Yoshio
    Mishima, Michiaki
    Chin, Kazuo
    Mimori, Tsuneyo
    Hirai, Toyohiro
    RHEUMATOLOGY, 2019, 58 (08) : 1465 - 1473
  • [5] Interstitial lung disease in polymyositis and dermatomyositis
    I-Jung Chen
    Yeong-Jian Jan Wu
    Cho-Wei Lin
    Kang-Wei Fan
    Shue-Fen Luo
    Huei-Huang Ho
    Lieh-Bang Liou
    Wen-Pin Tsai
    Ji-Yih Chen
    Chung-Han Yang
    Chang-Fu Kuo
    Kuang-Hui Yu
    Clinical Rheumatology, 2009, 28 (6) : 639 - 646
  • [6] Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease
    Hozumi, Hironao
    Fujisawa, Tomoyuki
    Nakashima, Ran
    Johkoh, Takeshi
    Sumikawa, Hiromitsu
    Murakami, Akihiro
    Enomoto, Noriyuki
    Inui, Naoki
    Nakamura, Yutaro
    Hosono, Yuji
    Imura, Yoshitaka
    Mimori, Tsuneyo
    Suda, Takafumi
    RESPIRATORY MEDICINE, 2016, 121 : 91 - 99
  • [7] Interstitial lung disease in polymyositis and dermatomyositis.
    Marie, I
    Dominique, S
    Rémy-Jardin, M
    Hatron, PY
    Hachulla, E
    REVUE DE MEDECINE INTERNE, 2001, 22 (11): : 1083 - 1096
  • [8] Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis
    Kang, EH
    Lee, EB
    Shin, KC
    Im, CH
    Chung, DH
    Han, SK
    Song, YW
    RHEUMATOLOGY, 2005, 44 (10) : 1282 - 1286
  • [9] Interstitial lung disease in polymyositis/dermatomyositis
    Schnabel, A.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 (03): : 220 - +
  • [10] Interstitial lung disease in polymyositis/dermatomyositis
    Schnabel, A.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 (03): : 220 - +